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undertaking the learning activity 
is equivalent to 60 minutes of 
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Introduction
Novel psychoactive substances (NPS) or the 
so-called ‘legal highs’ are emerging rapidly 
worldwide, as are concerns about NPS abuse. 
NPS have been a growing trend over the 
past decade for a number of reasons, including 
difficulties detecting them in routine urine drug 
screens, legal loopholes, easy access through 
the internet and low cost1.
Labelling these drugs as ‘herbal highs’ or 
‘legal highs’ is misleading as there is nothing 
natural about these synthetic and untested 
drugs and also currently none of them are 
legal in New Zealand2. But there has been an 
explosion in numbers of NPS worldwide with 
the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) reporting this year 
that it is now monitoring 560 NPS and 98 new 
substances that were reported for the first in 
2015 and 101 in 20143.
There are several typical categories of NPS 
drugs including synthetic cathinones (e.g. 
mephedrone and MDPV), plant-based NPS 
(e.g. khat and salvia divinorum), synthetic 
cannabinoids (e.g ‘Spice’, ‘Kronic’ and ‘K2’), and 
‘party’ drugs like benzylpiperazine (BZP).
Synthetic drugs can be taken through 
insufflation (snorting), oral ingestion and rectal 
insertion, as well as being taken intravenously, 
intramuscularly and subcutaneously.
These drugs are considered to have an effect 
on mental health wellbeing. Identified mental 
The use of novel psychoactive substances (NPS) or ‘legal highs’ 
is an emerging issue worldwide. There is rising concern around 
the risks of NPS and the detrimental effects on individuals’ 
mental health. How can you as a nurse identify and manage 
risks around NPS in your everyday nursing practice?
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Learning outcomes
Reading and reflecting on this article will enable you to:
 » increase your knowledge of novel psychoactive 
substances (NPS) and how they affect mental health
 » identify potential physical health and mental health 
risks resulting from NPS use for clients in your area 
of nursing
 » increase your understanding of co-existing 
substance use and mental health problems and 
some approaches to managing clients that misuse 
substances like NPS.
health symptoms that can result from NPS use 
are low mood, confusion, and anxiety1. 
The European Monitoring Centre for Drugs 
and Drug Addiction (EMCDDA)4 identified 
synthetic cannabinoids as prominent in 
affecting mood and perception and that 
intoxications can cause agitation, tachycardia, 
and arterial hypertension. The centre says that 
synthetic cannabinoids are 100 times more 
powerful than traditional strains of cannabis4. 
The EMCDDA also identified synthetic 
cathinones as hallucinogenic stimulants with 
cardiovascular and psychiatric side effects. 
The number of deaths involving NPS 
increased by 15 per cent in 2013 in the United 
Kingdom, with 60 deaths, up from 52 deaths 
in 20125. New Zealand attempted temporary 
bans on different NPS before passing the 
Psychoactive Substances Act in 2013, which 
puts the responsibility on NPS producers or 
importers to prove they are low risk6. At present 
no NPS products are legally available for 
sale in New Zealand2, but the the ingredients 
for making illicit drugs are still available for 
purchase on untraceable internet sites so 
access to NPS continues.
Detection of NPS use can be difficult as adult 
users – who usually present with agitation, 
cardiovascular and psychiatric symptoms – 
can often pass urine drug screening due to 
the lack of detectable metabolites. To further 
complicate matters, the molecular makeup 
of NPS drugs can be changed slightly to make 
detection through urine drug screening tests 
even more difficult7. 
It has been suggested that health 
professionals, for example, in emergency 
departments, primary health and mental health 
services, need to be made aware of the growing 
levels of NPS misuse so that it can be identified 
and treated accordingly7.
Examples of NPS and the risks they 
could pose to the people you nurse
It is useful for nurses to have an understanding 
of the potential risks of NPS. Nurses also 
need to maintain a therapeutic relationship 
that is respectful of the individual’s choices, 
experiences and expertise11,12.
This section looks at some of the NPS 
currently available.
Synthetic cathinones
Mephedrone is one of a group of synthetic 
cathinone drugs that are chemically 
similar to amphetamines. Another is 
methylenedioxypyrovalerone (MDPV). Synthetic 
cathinones can result in the stimulation of 
psychosis, neurological and other health 
complications. Mental health professional 
intervention is needed for people with mental 
health problems as a result of mephedrone 
misuse. 
Synthetic cathinones have been found to 
have similar effects to psychostimulatory drugs 
of misuse including cocaine, amphetamine and 
MDMA (ecstasy). Psychiatric symptoms as a 
result of mephedrone/cathinone misuse include 
aggression, agitation, anhedonia, anxiety, 
confusion, delusions, depression, dysphoria, 
irritability, loosening of association, mental 
fatigue, panic attacks, paranoia, perceptual 
distortion, psychosis, self-mutilation, suicidal 
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thoughts/suicide and visual and auditory 
hallucinations. Addictive symptoms identified 
include tolerance, craving and withdrawal 
syndrome13.
’N-Bomb’ or NBOMe
The psychedelic drug commonly known as 
‘N-Bomb’ (25I-NBOMe, 2C-I-NBOMe) is a 
powerful hallucinogen that has been prevalent 
in New Zealand since 201214. N-Bomb’s high 
potency increases risks of toxicity in small 
doses. Common routes of administration 
include sublingual, buccal, and nasal/
intranasal15. 
The hallucinogenic effects of N-Bombs mimic 
LSD and can last between six and 10 hours and 
include feelings of euphoria, mental and physical 
stimulation, a pleasant or positive change in 
consciousness and unusual body sensations. 
Risks include tachycardia, hypertension, pyrexia, 
agitation, hallucinations, seizures and death. 
There have been media reports in New Zealand 
of renal and cardiovascular complications 
following use and overseas there have been a 
number of N-Bomb-related deaths14. 
Spice and other synthetic cannabinoids
The misuse of ‘Spice’ or synthetic cannabinoids 
is increasing among teenagers and adults. Spice 
has over 220 compounds in various different 
combinations or brands16. There is also a risk of 
Spice causing psychopathological disturbances, 
namely psychosis, causing what is known as 
“Spiceophrenia”. 
Spice can affect a person’s physical state 
and can trigger vomiting, seizures, tachycardia, 
mydriasis, hypertension, confusion and 
restlessness. Mental health symptoms include 
delusions, paranoia, disorganised thought and 
visual and auditory hallucinations. Fluctuating 
mood, anxiety, perception, thinking, memory, 
and attention is common. Agitation, panic, 
dysphoria, psychosis and bizarre behaviour are 
also common17. 
Why may people who experience MH 
issues use NPS?
There are various reasons for the prevalence 
of people with mental health problems abusing 
illicit substances like NPS. This includes the 
cheap availability of NPS, accessibility and peer 
pressure1. 
Also, according to Ponizovsky et al18, people 
with co-existing problems are more at risk 
of non-adherence to prescribed medication 
and therefore more prone to relapse, 
rehospitalisation, and illicit drug and alcohol use.
One recent research study talks about 
mental health service users using illicit drugs 
to control their distressing symptoms, or to 
“relax” and to get “high”19. The findings of this 
empirical study suggest that substance use was 
related to controlling emotional states, anxiety, 
and depression. Alcohol was seen as less 
harmful than cannabis and other psychoactive 
compounds in the perception of the mentally 
ill substance user. Counteracting psychiatric 
medication side effects was also identified 
as a reason, alongside controlling psychotic 
states, i.e. managing auditory hallucinations by 
smoking more cannabis. So nurses should be 
aware that some clients may ‘manage’ mental 
health symptoms with illicit drugs and alcohol. 
Mental health professionals use a range of 
patient-centred and focused risk assessments 
that have been formulated specifically for 
people with co-existing problems9,20. 
One harm reduction approach to tackling 
NPS or other substance misuse, that can be 
done in non-specialist addiction settings like 
primary health, is using a brief assessment tool 
to assess whether alcohol or drug problems 
are at the ‘social or harmless use’ end of the 
continuum or the ‘moderate to severe’. This 
helps identify the level of intervention needed 
with mild problems usually just needing a 
brief intervention to reduce use to safe levels, 
while ‘moderate to severe’ problems require a 
comprehensive assessment and management 
plan9.
Co-existing problem approaches
The New Zealand guidelines for the 
assessment and management of co-existing 
problems9 take a client-centred approach. 
The guidelines set out seven key principles, 
including screening all clients presenting in 
mental health and addiction services for CEP 
and, if positive, undertaking a comprehensive 
assessment that gives equal weight to both 
mental health and substance use problems. 
Also emphasised is safety, stabilisation, 
engaging with clients by developing a ‘trusting, 
empathetic and non-judgemental therapeutic 
Mental health problems are widely associated with substance misuse, including the use of legal 
highs. There are a range of terms used to describe this combination of problems, including 
dual diagnosis, but the term ‘co-existing substance use and mental health problems’, or co-
existing problems (CEP) for short, is used in New Zealand with ‘co-existing’ chosen as it implies 
interaction more than ‘co-occurring’8.
CEP are highly prevalent in therapeutic settings in New Zealand with an estimated third to half 
of all tangata whaiora (service clients) in mental health settings likely to have current CEP and 
up to three-quarters of clients seeing addiction services9. People with severe CEP experience 
higher rates of institutionalisation, more failed treatment attempts, poverty, homelessness and 
risk of suicide8. 
It is estimated that 40 per cent of people with psychosis also have substance misuse 
problems. People with co-existing substance use and mental health disorders have higher rates 
of unmet needs and a higher rate of relapse and hospitalisation than those who primarily have 
psychosis10. 
It has been identified that some people with psychosis commonly misuse non-prescribed 
medication to deal with persisting psychiatric symptoms, which ultimately exacerbate 
NPS drug Effects of drug
Stimulant ‘legal highs’
These act in similar ways to cocaine, ecstasy or 
amphetamines.
Examples include: benzylpiperazine, Benzo Fury, 
party powder, mephedrone, TNT, legal ecstasy and 
legal speed.
 » Raised energy levels & euphoria
 » Rapid thoughts
 » Paranoia
 » Confusion & anxiety
 » Psychosis
 » Effect on the heart as well as the immune 
and nervous systems. The potential cause of 
tachycardia, bradycardia, high blood pressure, 
respiratory rate and pulse.
Sedative or downer ‘legal highs’
These work and act in a similar way to 
benzodiazepines. 
They include: Spice, Kronic (and other synthetic 
cannabinoids), GHB, V8 (ex-Fast Lane – legal 
coke), Mello Man (opium effect), Space Trips (LSD 
substitute), Hi-Octane (energy pills), TNT (speed), 
Big Daddy (ecstasy) and Sex Intense pills (sex party 
pills).
 » Similarities to cannabis
 » Euphoria
 » Sedation
 » Reduced disinhibition
 » Confusion, panic and dissociative effects. Can 
cause unconsciousness, coma and death, 
particularly when mixed with alcohol and/or other 
downer drugs.
 » Anxiety is common in people misusing downers, 
and severe withdrawal syndrome may develop in 
regular or heavy drug users. 
Psychedelic or hallucinogenic ‘legal highs’
These have effects similar to those of magic 
mushrooms, LSD. 
Examples include: ketamine, N-bomb, 3-MeO-PCP, 
Space Trips, Bubble Bud, Druids Fantasy, Space 
Cadets and Salvia divinorum.
 » Feelings of euphoria, warmth and dissociation
 » Hallucinations, some leading to ‘bad trips’
 » Confusion, anxiety and panic. Altered perceptions
 » Dissociative effects are common and users 
sometimes have an ‘out of body’ experience.
CO-EXISTING PROBLEMS
TIPS FOR AWARENESS AND DETECTION OF NPS USE
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relationship’, taking cultural needs and general 
wellbeing into consideration; and that CEP 
management should include strategies to 
enhance motivation, deliver interventions 
appropriate to the nature and severity of the 
problems, and provide integrated care9.
Barriers to CEP treatment can be 
prevalent across health settings due to 
miscommunication, lack of awareness and 
inappropriate referrals between mental health, 
substance misuse and community services8. 
There is a need for co-ordination between 
services, effective policies, protocols and 
effective clinical leadership. A clear referral 
pathway to addiction and mental health 
services is also needed8. 
Psychosocial interventions helpful 
for clients who use NPS
Psychosocial interventions can be beneficial 
in the treatment of substance use problems 
including NPS. 
The traditional approach for treating drug 
problems includes medication approaches and 
psychosocial (psychology-based) interventions. 
Psychosocial interventions include treatments 
such as cognitive behavioural therapy (CBT) 
that aims to modify cognitive processes and 
behaviour21 and can be used as an approach to 
enhance subjective wellbeing8.
Motivational interviewing (MI) is a common 
psychosocial intervention aimed at enhancing 
motivation and readiness for treatment. Miller 
and Rollnick define motivational interviewing as 
a non-judgmental, non-confrontational and non-
adversarial approach that enhances a person’s 
awareness of the problems caused and the 
consequences experienced as a result of their 
behaviour e.g. alcohol dependence22. 
Motivation – including strategies to enhance 
motivation like CEP-adapted motivational 
interviewing (MI) – is one of the seven key 
principles of CEP treatment in New Zealand9. 
New developments in MI include an increased 
emphasis on the client’s hopes and values and 
structured first interviews aimed at enhancing 
engagement in treatment9. 
Contingency management is another 
psychosocial technique that provides a system 
of incentives or reinforcement to encourage 
abstinence. Dutra et al23 suggest drug 
abstinence increased by using strategies such 
as food vouchers, money or other incentives for 
positive behaviour. Other emerging psychosocial 
approaches that the 2010 New Zealand 
guidelines say show promise include kaupapa 
Māori approaches, mindfulness, and acceptance 
and commitment therapy9.
Conclusion 
Mental health problems as a result of adults 
misusing novel psychoactive substances (NPS) 
are emerging around the world and in  
New Zealand. Despite law changes, NPS – 
and the ingredients to make illicit drugs – are 
available to purchase on hidden internet sites 
that are untraceable to law enforcement 
worldwide. 
There is a push in New Zealand to address 
co-existing problems (CEP) of mental health and 
substance use with strategies and guidelines8,9 
and an updated blueprint for mental health24.
CEP is highly prevalent in New Zealand and 
NPS is a newly contributing factor. Therefore it 
is important that nurses have a knowledge and 
understanding of substance use and CEP issues 
in general, including the common effects and 
risks of NPS use.
Collaboration and partnerships between 
mental health, addiction, primary care and other 
areas of nursing are essential to providing a 
safe and harm reduction approach to substance 
misuse. Monitoring, early detection, engagement 
with clients and using suitable interventions are 
very important in minimising harm from NPS 
and other substance use. These approaches are 
inherent to the addiction nursing framework25, 
the mental health nursing standards of practice 
and the New Zealand College of Mental Health 
Nurses credentialing programme for primary 
care nurses26.
At present the research on managing NPS 
misuse is limited and there is a need to identify 
interventions that health professionals agree can 
work in managing co-existing problems resulting 
from NPS misuse. Services also need to respond 
early to communication problems and interface 
issues between services that can create barriers 
for CEP clients receiving access to mental health 
and drug treatments. 
Poor mental health is disempowering for 
substance users and health professionals need 
to acknowledge personal experiences, empower 
recovery and improve the quality of life for 
people with mental health issues11,12.
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